Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
- Author:
In Cheol YOON
1
;
Jong Ryeol EUN
Author Information
- Publication Type:Review
- Keywords: Drug therapy; Nonalcoholic steatohepatitis; Pathophysiology
- MeSH: Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Diet; Drug Therapy; Dyslipidemias; Fibrosis; Hepatitis B; Humans; Insulin Resistance; Korea; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Obesity; United States; Weight Loss
- From:Yeungnam University Journal of Medicine 2019;36(2):67-77
- CountryRepublic of Korea
- Language:English
- Abstract: The paradigm of chronic liver diseases has been shifting. Although hepatitis B and C viral infections are still the main causes of liver cirrhosis and hepatocellular carcinoma (HCC), the introduction of effective antiviral drugs may control or cure them in the near future. In contrast, the burden of nonalcoholic fatty liver disease (NAFLD) has been increasing for decades, and 25 to 30% of the general population in Korea is estimated to have NAFLD. Over 10% of NAFLD patients may have nonalcoholic steatohepatitis (NASH), a severe form of NAFLD. NASH can progress to cirrhosis and HCC. NASH is currently the second leading cause to be placed on the liver transplantation list in the United States. NAFLD is associated with obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. The pathophysiology is complex and associated with lipotoxicity, inflammatory cytokines, apoptosis, and insulin resistance. The only proven effective treatment is weight reduction by diet and exercise. However, this may not be effective for advanced fibrosis or cirrhosis. Therefore, effective drugs are urgently needed for treating these conditions. Unfortunately, no drugs have been approved for the treatment of NASH. Many pharmaceutical companies are trying to develop new drugs for the treatment of NASH. Some of them are in phase 2 or 3 clinical trials. Here, pharmacologic therapies in clinical trials, as well as the basic principles of drug therapy, will be reviewed, focusing on pathophysiology.
